Trulicity ® (dulaglutide) injection

0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

United States Prescribing Information - Trulicity® (dulaglutide) REWIND Study Label Updates [Video]

The REWIND cardiovascular outcomes trial provided important information used to update the Trulicity USPI. Dr. Sherry Martin will discuss these additions.

Date of Last Review: October 08, 2020

Document Number: VV-MED-93511

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical